REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Anti-Aging Skin Stack

Anti-Aging & Longevityintermediate

83

synergy

83
Peptides

3

Avg Daily mcg

5,800

Level

intermediate

Added

May 17, 2026

Overview

The Anti-Aging Skin Stack combines the three most evidence-backed peptides for skin aging and longevity into a comprehensive protocol that targets collagen synthesis, cellular aging, and GH-driven tissue regeneration simultaneously. GHK-Cu (glycyl-L-histidyl-L-lysine copper) is the anchor of this stack. As a copper-binding tripeptide that naturally declines with age (from ~200ng/mL at age 20 to ~80ng/mL at 60), GHK-Cu activates over 4,000 human genes — more than any other known compound. For skin, it promotes collagen and elastin synthesis, activates fibroblasts, reduces inflammation, and protects against UV damage. Both topical and injectable forms have peer-reviewed human data supporting skin quality improvements. Epithalon works at the cellular aging level. By activating telomerase and regulating the pineal gland''s circadian signaling, it slows two fundamental mechanisms of skin aging: telomere shortening (which drives cellular senescence) and circadian rhythm disruption (which impairs the nighttime skin repair cycle). Epithalon is used in 10-day courses rather than continuously. CJC-1295 provides the GH axis component. GH decline is one of the primary drivers of skin thinning, reduced collagen density, and decreased healing capacity with age. By amplifying nocturnal GH pulses, CJC-1295 increases IGF-1-driven collagen production throughout the body, including skin. The combination of GHK-Cu (direct collagen synthesis) and CJC-1295 (hormonal collagen support) creates a more sustained and comprehensive collagen protection effect.

Dosing Protocol

GHK-Cu

Every day· subcutaneous or topical

500 mcg

per dose

Epithalon

daily (10-day course)· subcutaneous

5,000 mcg

per dose

CJC-1295

daily (before bed)· subcutaneous

300 mcg

per dose

Goals & Evidence

Skin anti-agingCollagen productionReduced wrinklesSkin elasticityCellular longevity
Evidence tier:Human Data

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.